#ESMO22: Seagen builds case for Padcev-Keytruda combo in front-line bladder cancer

Lei Lei Wu

News Reporter

PARIS — In July, sandwiched in the back-and-forth rumors on a potential Merck buyout, Seagen posted a topline look at its Padcev-Keytruda combo as a first …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ESMO22: Seagen builds case for Padcev-Keytruda combo in front-line bladder cancer

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

GSK makes case for Blenrep's return with new blood cancer survival data

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

#ES­MO22: Seagen builds case for Pad­cev-Keytru­da com­bo in front-line blad­der can­cer

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

#ESMO22: Seagen builds case for Padcev-Keytruda combo in front-line bladder cancer

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

GSK makes case for Blenrep's return with new blood cancer survival data

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?